Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity

Abstract

Three years of follow up in a small series suggest that intravitreal ranibizumab injections for ROP result in apparently preserved ocular outcome. Further large scale studies are needed to address the long-term safety and efficacy.